Memphis-based GTx announced Tuesday morning that it had submitted a new drug application with the U.S. Food and Drug Administration for the prevention of bone fractures in men undergoing drug therapy for prostate cancer.
Bone loss is a side effect of androgen deprivation therapy (ADT), which is the primary treatment for advanced prostate cancer. GTx has filed an application for toremifene 80 milligrams, an oral selective estrogen receptor modulator Read the rest of this entry »
Palm Beach drug injury lawyer, Susan Ramsey, says Medicaid has unsafe drugs
West Palm Beach drug injury lawyer, Susan Ramsey, injury attorney says Medicaid allows unsafe drugs. FDA unapproved drugs allows injuries and deaths.
Medicaid, a division of the U.S. Government Centers for Medicare and Medicaid Services (CMS) http://www.cms.hhs.gov/, is a state administered program funded by the federal government. Medicaid provides medical coverage to Read the rest of this entry »
BEIJING, Dec. 29 (Xinhuanet) -- The Food and Drug
Administration (FDA) recently approved the first drug that will help with
producing longer eyelashes, according to media reports Monday.
Latisse, produced by the company of Allergan, is
supposed to treat those who have hypotrichosis, a condition in which a person
does not have enough eyelashes. It will be available by prescription starting in
the first quarter of 2009.
The active ingredient Read the rest of this entry »
(Updates with analyst comment, share price)
LONDON, Nov 28 (Reuters) - AstraZeneca Plc (AZN.L:
,
,
,
) faces a
delay in getting a new infant lung drug from its recently
acquired MedImmune biotech unit to market in the United States.
The Anglo-Swedish drugmaker said on Friday it had received a
so-called "complete response letter" from the U.S. Food and Drug
Administration (FDA) asking for additional information on
motavizumab.
The move Read the rest of this entry »
2008-11-08 16:36:29 (GMT) (Caymanmama.com - Health News News)
Atlanta, Georgia (CaymanMama.com) — It has never been more apparent that severe diet efforts and diet drugs promising exceptionally fast weight loss are fad and can cause more harm than good.
In a recent report by HealthDay, a new study concludes that one of the biggest obesity fad drugs “fen/phen” has been tied with heart valve damage that can develop years after Read the rest of this entry »
According to Drugs.com, the most controversial feature of Part D is the
benign-sounding donut hole. Also known as the coverage gap, it is an
abrupt discontinuation of benefits that occurs when drug costs (the
total paid by both the member and the plan) hit the $2700 mark. Once
this threshold is crossed, the member must bear the full cost of his or
her drugs - a heavy burden indeed. To many seniors, news of this Read the rest of this entry »
DALLAS —Seniors may see their Social Security increases next year trimmed back by higher prescription costs unless they shop for a Medicare drug plan this fall that better fits their budget.
Social Security beneficiaries will get an average of $63 more each month, but part of that increase may be claimed by higher premiums and out-of-pocket costs in their drug coverage.
“Seniors who enrolled in a drug plan several years ago should Read the rest of this entry »
When drug companies seek approval to market new medicines, they must show the U.S. Food and Drug Administration the results of all the tests they've run on volunteer patients - at first on only a few, then on dozens, and finally on hundreds or sometimes thousands.
After winning approval, the companies typically sponsor reports of those tests in medical journal publications, which many doctors often rely on to determine whether to prescribe new drugs Read the rest of this entry »
accused drug companies on Friday of adding billions of dollars to health care costs by delaying or blocking the sale of less expensive generic medicines.
One common tactic, said Neelie Kroes, the European competition commissioner, was for drug companies to amass patents to protect active ingredients in the medicines — in one case, 1,300 patents for a single drug. Another tactic, she said, was for pharmaceutical companies to sue the makers Read the rest of this entry »
-(Dow Jones)- Amid recent studies showing the anti-clotting drug
Plavix may not be effective for 30% of cardiac patients, federal regulators are
considering updating the drug's label to include information on genetic factors
that could interfere with the medicine.
Food and Drug Administration officials, however, said they aren't sure what
changes to make to the label and what to tell cardiologists to do because of a
variety of complications. To Read the rest of this entry »